Nationwide Registry of Patients With Heart Failure With Improved and Supranormal Ejection Fraction

NOVEL-HF is a multicenter, observational nationwide registry of HFimpEF and HFsnEF conducted in cooperation with the Scientific Platform of the Polish Society of Cardiology. According to the current definitions the criteria for HFimpEF diagnosis include patients with HF with an initial left ventricular ejection fraction (LVEF) below 40%, with at least a 10% increase during follow-up, and with final values \>40%. HFsnEF includes patients with HF whose LVEF values on echocardiography are \>65%. The patient data will be collected from standardized and anonymous forms via the Scientific Platform of the Polish Society of Cardiology. The NOVEL-HF registry will involve the complete clinical, laboratory, and echocardiographic characteristics, as well as introduced pharmacological treatment. The occurrence of end-points (all-cause mortality, cardiovascular mortality, HF decompensations, worsening of HF symptoms) will be assessed in short- and long-term follow-up. In accordance with initial assumptions, 500 HFimpEF and 200 HFsnEF patients in all participating centers will be included. Ethical approval was granted by the local Bioethics Committee.

NCT Number	NCT07389564
Lead Sponsor	Jagiellonian University
Conditions	Heart Failure
Enrollment	700 participants
Start Date	2026-01-29
Primary Completion	2026-08-01 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-05